Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study

项目总结 2018年NIA-阿尔茨海默病协会研究框架[AT(N)]为阿尔茨海默病(AD)提供了 通过整合淀粉样蛋白(A)、tau(T)和淀粉样蛋白(T)等最新生物标志物研究AD的生物学背景 神经变性(N)。尽管这些生物标记物因种族/民族不同而不同，但以前的工作都没有 对墨西哥裔美国人进行了系统的研究。鉴于(1)拉美裔/拉丁裔预计将 到2060年经历AD和阿尔茨海默病相关痴呆(ADRD)的最大增长(2) 墨西哥裔美国人是美国拉美裔/拉美裔人口中最大的一部分，迫切需要 研究这些生物标记物在这一代表性不足的人群中的患病率、进展和临床影响。 这项工作涉及国家阿尔茨海默氏症项目法(NPA)的目标，NIA关于AD和ADRD的里程碑 研究，以及AT(N)框架出版物所强调的需求。 目前的研究团队由墨西哥裔美国人认知老化、神经成像方面的顶尖专家组成。 (PET和MRI)、基于血液的生物标记物以及高级统计建模。通过利用正在进行的 Hable队列、基础设施和数据，我们将测试以下具体目标：目标1：检查 2018年AT(N)框架脑标记物的患病率、进展和临床影响 居住在社区的墨西哥裔美国人。目的2.检查该病的患病率、进展和临床影响 社区居住的墨西哥裔美国人2018年AT(N)框架的血液标志物。目标3：实现 确定Aβ40、Aβ42、tau和nfl的血液生物标志物是否可用于筛选AT(N)定义的 墨西哥裔美国人参加新的临床试验的临床前阿尔茨海默病、前驱阿尔茨海默病和阿尔茨海默病。 目前的研究具有重要意义，原因有几个：(1)这是有史以来第一次大规模的多种族 AT(N)生物标记物的研究，鉴于美国的种族/民族构成，这一研究具有极其重要的意义。 人口；(2)这项工作直接涉及国家适应行动方案和国家行动方案--AD/ADRD的里程碑 科学；(3)它将确定特定种族的生物标记物轨迹是否合适，最后，(4)它将 生成数据和方法，以增加AT(N)定义的拉美裔美国人参加临床试验的人数 从初级保健环境开始的AD(一级、二级和三级预防)的范围。

PROJECT SUMMARY The 2018 NIA - Alzheimer's Association Research Framework [AT(N)] for Alzheimer's Disease (AD) provides a biological context for studying AD by incorporating state-of-the art biomarkers of amyloid (A), tau (T) and neurodegeneration (N). Despite the fact that these biomarkers vary by race/ethnicity, no prior work has systematically examined them among Mexican Americans. Given that (1) Hispanic/Latinos are projected to experience the largest growth in AD and Alzheimer's Disease Related Dementias (ADRDs) by 2060 and (2) Mexican Americans are the largest segment of the U.S. Hispanic/Latino population, there is a pressing need to study prevalence, progression and clinical impact of these biomarkers among this underrepresented group. This work addresses goals of the National Alzheimer's Project Act (NAPA), NIA Milestones for AD and ADRD research, and needs highlighted by the AT(N) framework publication. The current research team consists of leading experts in Mexican American cognitive aging, neuroimaging (PET and MRI), blood-based biomarkers as well as advanced statistical modeling. By leveraging the ongoing HABLE cohort, infrastructure and data, we will test the following Specific Aims: Aim 1: Examine the prevalence, progression and clinical impact of cerebral markers of the 2018 AT(N) framework among community-dwelling Mexican Americans. Aim 2. Examine the prevalence, progression and clinical impact of blood markers of the 2018 AT(N) framework among community-dwelling Mexican Americans. Aim 3: To determine if blood-based biomarkers of Aβ40, Aβ42, tau and NfL can be used to screen for AT(N)-defined preclinical AD, prodromal AD and AD dementia for enrollment of Mexican Americans into novel clinical trials. The current study is highly significant for several reasons: (1) This is the first-ever large-scale multi-ethnic study of the AT(N) biomarkers, which is of tremendous importance given the racial/ethnic make-up of the U.S. population; (2) this work directly addresses goals set forth by NAPA as well NIA-Milestones for AD/ADRD science; (3) it will determine if ethnic-specific biomarker trajectories are appropriate and finally, (4) it will generate data and methods for increasing enrollment of Hispanics into clinical trials across the AT(N)-defined spectrum of AD (primary, secondary and tertiary prevention) beginning in primary care settings.